$TBPH
Theravance Biopharma Inc

2021 Q2 Form 10-Q Financial Statement

#000155837021010555 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $12.91M $15.01M $19.86M
YoY Change -13.95% -42.61% 272.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $25.93M $24.78M $26.33M
YoY Change 4.64% 11.49% 4.52%
% of Gross Profit
Research & Development $51.09M $62.40M $66.01M
YoY Change -18.13% 34.49% 22.66%
% of Gross Profit
Depreciation & Amortization $1.386M $1.610M $2.420M
YoY Change -13.91% 3.87% 83.33%
% of Gross Profit
Operating Expenses $77.02M $87.18M $92.34M
YoY Change -11.65% 27.04% 16.88%
Operating Profit -$64.11M -$72.18M -$72.48M
YoY Change -11.18% 69.92% -1.62%
Interest Expense $11.61M $11.39M $9.941M
YoY Change 1.94% 44.17% 26.51%
% of Operating Profit
Other Income/Expense, Net $1.171M -$662.0K $1.460M
YoY Change -276.89% -127.89% -47.76%
Pretax Income -$52.63M -$62.85M -$82.91M
YoY Change -16.27% 58.56% 14.35%
Income Tax -$220.0K $39.00K $147.0K
% Of Pretax Income
Net Earnings -$52.41M -$62.89M -$83.05M
YoY Change -16.67% 57.86% 14.43%
Net Earnings / Revenue -405.8% -419.02% -418.15%
Basic Earnings Per Share -$0.80 -$1.00 -$1.40
Diluted Earnings Per Share -$0.80 -$1.00 -$1.40
COMMON SHARES
Basic Shares Outstanding 65.67M 63.28M 60.08M
Diluted Shares Outstanding 65.67M 62.86M 59.46M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $265.0M $438.3M $487.0M
YoY Change -39.56% 10.67% 12.19%
Cash & Equivalents $204.9M $104.7M $332.8M
Short-Term Investments $60.00M $333.6M $154.2M
Other Short-Term Assets $28.27M $13.10M $5.500M
YoY Change 115.77% 47.19% -78.17%
Inventory
Prepaid Expenses
Receivables $12.22M $11.40M $14.20M
Other Receivables $27.74M $35.50M $27.50M
Total Short-Term Assets $333.2M $498.4M $534.2M
YoY Change -33.15% 16.98% 14.34%
LONG-TERM ASSETS
Property, Plant & Equipment $16.58M $14.43M $13.91M
YoY Change 14.9% 13.99% -77.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $35.82M $0.00 $5.100M
YoY Change
Other Assets $1.325M $1.508M $1.308M
YoY Change -12.14% 8.65% -43.13%
Total Long-Term Assets $96.07M $65.94M $71.19M
YoY Change 45.69% -0.7% 11.06%
TOTAL ASSETS
Total Short-Term Assets $333.2M $498.4M $534.2M
Total Long-Term Assets $96.07M $65.94M $71.19M
Total Assets $429.3M $564.3M $605.4M
YoY Change -23.94% 14.6% 13.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.70M $10.07M $6.645M
YoY Change 6.33% 187.49% 18.66%
Accrued Expenses $43.79M $71.40M $68.20M
YoY Change -38.66% 40.0% 19.44%
Deferred Revenue $5.690M $25.06M $23.19M
YoY Change -77.3% -42.13%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.941M $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $67.13M $106.6M $98.04M
YoY Change -37.01% -3.23% -13.62%
LONG-TERM LIABILITIES
Long-Term Debt $602.6M $601.7M $600.0M
YoY Change 0.14% 35.79% 34.38%
Other Long-Term Liabilities $1.833M $9.614M $9.583M
YoY Change -80.93% -33.5% -88.66%
Total Long-Term Liabilities $1.833M $9.614M $9.583M
YoY Change -80.93% -33.5% -98.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.13M $106.6M $98.04M
Total Long-Term Liabilities $1.833M $9.614M $9.583M
Total Liabilities $68.96M $116.2M $107.6M
YoY Change -40.65% -6.75% -83.3%
SHAREHOLDERS EQUITY
Retained Earnings -$1.659B -$1.395B -$1.332B
YoY Change 18.94% 24.01%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$300.4M -$202.3M -$157.9M
YoY Change
Total Liabilities & Shareholders Equity $429.3M $564.3M $605.4M
YoY Change -23.94% 14.6% 13.95%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$52.41M -$62.89M -$83.05M
YoY Change -16.67% 57.86% 14.43%
Depreciation, Depletion And Amortization $1.386M $1.610M $2.420M
YoY Change -13.91% 3.87% 83.33%
Cash From Operating Activities -$50.11M -$53.35M -$55.10M
YoY Change -6.08% 11.08% -32.14%
INVESTING ACTIVITIES
Capital Expenditures -$153.0K -$2.370M -$950.0K
YoY Change -93.54% 308.62% -22.13%
Acquisitions
YoY Change
Other Investing Activities $35.93M -$174.2M $69.36M
YoY Change -120.62% 24097.22% -197.77%
Cash From Investing Activities $35.76M -$176.6M $68.40M
YoY Change -120.25% 13483.85% -194.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $139.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 105.3M 1.880M 261.4M
YoY Change 5500.37% -57.27% -18343.68%
NET CHANGE
Cash From Operating Activities -50.11M -53.35M -55.10M
Cash From Investing Activities 35.76M -176.6M 68.40M
Cash From Financing Activities 105.3M 1.880M 261.4M
Net Change In Cash 90.94M -228.1M 274.7M
YoY Change -139.88% 407.59% -277.49%
FREE CASH FLOW
Cash From Operating Activities -$50.11M -$53.35M -$55.10M
Capital Expenditures -$153.0K -$2.370M -$950.0K
Free Cash Flow -$49.95M -$50.98M -$54.15M
YoY Change -2.01% 7.44% -32.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001583107
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64328000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73470000
dei Document Type
DocumentType
10-Q
dei Entity Address Country
EntityAddressCountry
KY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
KY1-1104
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
808-6000
dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
dei Trading Symbol
TradingSymbol
TBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity File Number
EntityFileNumber
001-36033
dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 309
dei Entity Address City Or Town
EntityAddressCityOrTown
George Town, Grand Cayman
CY2021Q2 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
12220000
CY2020Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
15868000
CY2021Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
27741000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
53799000
CY2021Q2 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
15913000
CY2020Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
20374000
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
12353000
dei Entity Address Address Line2
EntityAddressAddressLine2
Ugland House, South Church Street
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73470151
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204949000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81467000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
60004000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
211474000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10359000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
333180000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
393341000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16583000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16422000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41508000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43260000
CY2021Q2 us-gaap Equity Method Investments
EquityMethodInvestments
35822000
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
12750000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1325000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2451000
CY2021Q2 us-gaap Assets
Assets
429251000
CY2020Q4 us-gaap Assets
Assets
469057000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10702000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6775000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14635000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
35238000
CY2021Q2 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
19457000
CY2020Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
28799000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12914000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15008000
CY2021Q2 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
3269000
CY2020Q4 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
6048000
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
3900000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3974000
CY2021Q2 tbph Non Recourse Debt Due2035 Current
NonRecourseDebtDue2035Current
6941000
CY2020Q4 tbph Non Recourse Debt Due2035 Current
NonRecourseDebtDue2035Current
19334000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1037000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9867000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5690000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11523000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1496000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2013000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
67127000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
123571000
CY2021Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
227499000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
226963000
CY2021Q2 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
375069000
CY2020Q4 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
372873000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57768000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47220000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
329000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
348000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1833000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1833000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73470000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64328000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1358318000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1222818000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
47000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1658701000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1526617000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-300374000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429251000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469057000
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
21381000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
38473000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
34896000
CY2021Q2 us-gaap Interest Expense
InterestExpense
11612000
CY2020Q2 us-gaap Interest Expense
InterestExpense
11391000
us-gaap Interest Expense
InterestExpense
23485000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27171000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34870000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51093000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62404000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118692000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
128417000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25931000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24780000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
56481000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51105000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
77024000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
87184000
us-gaap Operating Expenses
OperatingExpenses
175173000
us-gaap Operating Expenses
OperatingExpenses
179522000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-64110000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-72176000
us-gaap Operating Income Loss
OperatingIncomeLoss
-148002000
us-gaap Operating Income Loss
OperatingIncomeLoss
-144652000
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
21926000
us-gaap Interest Expense
InterestExpense
21332000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1171000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-662000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
937000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
798000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52625000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62848000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-132077000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145754000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-220000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
186000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-52405000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-62887000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
us-gaap Net Income Loss
NetIncomeLoss
-145940000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-232000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
135000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52414000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63119000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132123000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-145805000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.39
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65669000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62861000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65085000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61162000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14941000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16585000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30773
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31861000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-373218000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108180000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2862000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14941000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
727000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-52405000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-300374000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108180000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2862000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30773000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6320000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-300374000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-157936000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2545000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16585000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
733000
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1144000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-232000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-62887000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-202336000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
139915000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2545000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31861000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
936000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
7948000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
135000
us-gaap Net Income Loss
NetIncomeLoss
-145940000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-202336000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
us-gaap Net Income Loss
NetIncomeLoss
-145940000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
2926000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4034000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
-31000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
854000
us-gaap Share Based Compensation
ShareBasedCompensation
30773000
us-gaap Share Based Compensation
ShareBasedCompensation
31861000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1752000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1420000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
-2986000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
6934000
tbph Interest Shortfall On2035 Notes
InterestShortfallOn2035Notes
1093000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
168000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-3648000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-10583000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
-4461000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
5775000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1993000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
264000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-997000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
373000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4026000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6012000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-33125000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5753000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-74000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1957000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5852000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12120000
tbph Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1718000
tbph Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
885000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
175000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119978000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108447000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1923000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3322000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
40014000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
280495000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
191400000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
155703000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19927000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
149463000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108186000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108180000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139915000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
380000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5326000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10730000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
11470000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
235347000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2862000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2545000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
936000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6320000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7948000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93997000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
263305000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
123482000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46671000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82300000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58897000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205782000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105568000
us-gaap Interest Paid Net
InterestPaidNet
22490000
us-gaap Interest Paid Net
InterestPaidNet
20287000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65199000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61676000
CY2020Q2 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-414000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-52405000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-62887000
us-gaap Net Income Loss
NetIncomeLoss
-132084000
us-gaap Net Income Loss
NetIncomeLoss
-145940000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65669000
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63275000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-114000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-514000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65669000
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62861000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65085000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61162000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.39
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12904000
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12389000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14983000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12417000
CY2018Q1 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.33
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
CY2021Q2 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1260000
CY2020Q2 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1914000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
2686000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
4392000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
44420000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204949000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104735000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
833000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
833000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205782000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105568000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
235489000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
235497000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
211427000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
53000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211474000
tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P6M
tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P1M
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
44420000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
6000
CY2021Q2 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0
CY2020Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5000000.0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
19900000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
609509000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2021Q2 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2021Q2 us-gaap Share Price
SharePrice
15.00
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7705000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
115600000

Files In Submission

Name View Source Status
0001558370-21-010555-index-headers.html Edgar Link pending
0001558370-21-010555-index.html Edgar Link pending
0001558370-21-010555.txt Edgar Link pending
0001558370-21-010555-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20210630.xsd Edgar Link pending
tbph-20210630x10q.htm Edgar Link pending
tbph-20210630x10q_htm.xml Edgar Link completed
tbph-20210630xex31d1.htm Edgar Link pending
tbph-20210630xex31d2.htm Edgar Link pending
tbph-20210630xex32.htm Edgar Link pending
tbph-20210630_cal.xml Edgar Link unprocessable
tbph-20210630_def.xml Edgar Link unprocessable
tbph-20210630_lab.xml Edgar Link unprocessable
tbph-20210630_pre.xml Edgar Link unprocessable